UPDATE 1-Payers see price leverage with entry of Merck hepatitis C drug 29.01.2016 23:57 Reuters Jan 29 (Reuters) - U.S. health insurers and pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.
